Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
132 studies found for:    coronado
Show Display Options
Rank Status Study
1 Withdrawn TSO for Plaque Psoriasis
Condition: Plaque Psoriasis
Intervention: Biological: Trichuris Suis Ova
2 Unknown  Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Condition: Crohn's Disease
Interventions: Biological: Trichuris suis ova (TSO);   Biological: Placebo
3 Unknown  Trichuris Suis Ova in Autism Spectrum Disorders
Condition: Autism
Intervention: Drug: Trichuris Suis Ova
4 Terminated Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder
Condition: Autism
Interventions: Biological: Trichuris suis ova;   Other: Placebo
5 Unknown  CNDO-109-AANK for AML in First Complete Remission (CR1)
Condition: Acute Myeloid Leukemia
Intervention: Biological: CNDO-109-AANK Cells
6 Completed
Has Results
Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease
Condition: Crohn's Disease
Interventions: Biological: Trichuris suis ova;   Other: Placebo
7 Completed A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection
Conditions: Hepatitis C Viral Infection;   Chronic Hepatitis C;   Hepatitis C (HCV);   Hepatitis C Genotype 4
Interventions: Drug: Faldaprevir;   Drug: TD-6450;   Drug: Ribavirin
8 Active, not recruiting Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics
Conditions: Hepatitis C;   Cirrhosis
Interventions: Drug: daclatasvir;   Drug: Sofosbuvir, Sovaldi;   Drug: Ribavirin
9 Completed
Has Results
The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin
Condition: Epilepsy
Interventions: Drug: BIA 2-093;   Drug: Placebo;   Drug: Digoxin
10 Completed
Has Results
Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Metformin in Healthy Volunteers
Condition: Neuropathic Pain
Interventions: Drug: Metformin;   Drug: Eslicarbazepine acetate
11 Completed Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg
Condition: Parkinson Disease
Interventions: Drug: Placebo;   Drug: BIA 6-512;   Drug: Madopar® 250;   Drug: Nebicapone
12 Completed Effect of Food on BIA 6-512 (Trans-resveratrol)
Condition: Parkinson Disease
Intervention: Drug: BIA 6-512 400 mg
13 Completed Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics
Condition: Parkinson Disease
Interventions: Drug: Placebo;   Drug: BIA 6-512;   Drug: Madopar® 250;   Drug: Comtan®
14 Completed Tolerability and Steady-state Pharmacokinetics of BIA 6-512
Condition: Parkinson Disease
Interventions: Drug: BIA 6-512;   Drug: Placebo
15 Completed Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics
Condition: Parkinson Disease
Interventions: Drug: Placebo oral capsule;   Drug: Sinemet® 100/25;   Drug: Comtan®;   Drug: BIA 6-512 25 mg;   Drug: BIA 6-512 100 mg
16 Completed Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics
Condition: Parkinson Disease
Interventions: Drug: Madopar® HBS 125;   Drug: Placebo;   Drug: BIA 6-512 25 mg dose;   Drug: BIA 6-512 50 mg dose;   Drug: BIA 6-512 100 mg dose;   Drug: BIA 6-512 200 mg dose
17 Completed Effect of BIA 3-202 on the Pharmacokinetics and Pharmacodynamics of Warfarin
Condition: Healthy
Interventions: Drug: BIA 3-202;   Drug: warfarin
18 Completed Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide
Condition: Parkinson's Disease (PD)
Interventions: Drug: BIA 3-202;   Drug: Placebo;   Drug: levodopa 100 mg / benserazide 25 mg
19 Completed Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers
Condition: Epilepsy
Interventions: Drug: BIA 2-093;   Drug: Gliclazide
20 Completed Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa
Condition: Parkinson's Disease
Interventions: Drug: BIA 3-202;   Drug: Placebo;   Drug: Sinemet®

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.